Skip to Content
NCI Patient-Derived Models Repository (PDMR) - An NCI Precision Oncology Initiative Resource
Contact PDMR
Show menu
Search this site
Last Updated: 04/17/19

ANNOUNCEMENT: NCI's Patient Derived Models Repository (PDMR) is once again able to accept requests for PDX material. All distribution lot PDX material has been tested and proven to be mouse kidney parvovirus (MKPV) negative. We have now incorporated testing of MKPV into our standard murine pathogen screen and this will be present on future updates to our posted Animal Facility Health Reports located on the SOP webpage. Distribution lot material for cell line (PDC, CAF) and organoid (PDOrg) cultures are going through screening for MKPV to confirm that those are also negative and we plan to re-open distribution of that material within 2-3 weeks. For further information about this new atypical strain of mouse parvovirus see the links below.

Announcement Date: 4/17/2019

Link to recent publication by Roedinger et al.

Link to IDEXX Mouse Opti-XXPress test

Information for Requesting In Vitro and Organoid Material

Request Process

  1. Initial distribution will be DOMESTIC ONLY, International distribution will follow. International requestors can request to be placed on a notification list once models can be distributed internationally.
  2. Fill out a PDMR In Vitro Model Request Form.
  3. Provide no more than a 2-page summary of the research plan for the requested material on the PDMR Model Request Form
    • If requesting CAF cultures, be sure to supply sufficient justification why the proposed research should be considered over other requestors. CAFs are non-renewable by the PDMR and once distribution material is used up, no further material will be available.
  4. If the recipient wishes to expand into other media than the Complete Media specified in the Certificate of Analysis provided with the requested cultures or on non-Matrigel coated flasks, the recipient should first establish a stock of viably cryopreserved vials of cells per the PDMR SOP and then test viability in alternate media conditions.
  5. Currently the PDMR can only accept payments via checks. No electronic funds transfers can be accepted (see payment procedures in PDMR In Vitro Material Request Procedures document).
  6. Complete Appendix 2 in the Material Transfer Agreement (MTA) with all PDC, CAF, and/or Organoid model Distribution Lot names listed. Send the MTA with signatures affixed from both the requestor and authorizing official (required by NCI). Modifications to NCI's MTA will not be considered.
    • Note: For standard requests for research-use of PDMR material, the check-box in bullet #3 does not need to be checked. This is for specific use-case collaborations set-up by the NCI.
  7. Intramural investigators (MD campus) need to complete the Request Form and Intramural MTA and will go through the same review process as all other Requestors; Intramural investigators can leave the FedEx and Payment Information blank.

Citing NCI Patient-Derived Models and Associated Data

  • To cite the PDMR, use a format similar to that shown below:

    The NCI Patient-Derived Models Repository (PDMR), NCI-Frederick, Frederick National Laboratory for Cancer Research, Frederick, MD. URL http://www.pdmr.nci.gov.

  • The full distribution lot name should be used in the publication (e.g., 123456-001-R-J1-PDC), not an abbreviated form. In addition, the lot# received and the passage of material used for analysis should be cited.
  • Any modifications to the distributed model should be identified (e.g., transfection, CRISPR, etc.).
  • Sequence files downloaded for use in analysis should be referenced including the version# listed in the file name as different pipeline versions may result in different interpretations of the data (e.g., v1.2, v1.3, v2.0.1.51.0).

Information

  • All NCI Patient-Derived Models Repository (PDMR) in vitro and organoid cultures are tested for sterility and confirmed mycoplasma free.
  • Viably cryopreserved Patient-Derived Tumor Cultures (PDCs) and Cancer-Associated Fibroblasts (CAFs) cultures contain a minimum of 7.5 x 105 cells. Viably cryopreserved Patient-Derived Organoid cultures (PDOrg) contain a minimum of 1-5 x 105 cells. These vials should be immediately placed in LN2 Vapor Phase (-180C); Do not store at -80C.
  • Read the provided Certificate of Analysis for details on the culture and access the Complete Media recipe for the specific culture that was requested on the PDMR SOP page. Do not thaw cells until the Complete Media has been prepared and PDMR SOPs for thawing, banking, and cryopreserving material have been read in total.
  • Cells should always be thawed using the PDMR SOPs into the recommended media. Failure to follow these SOPs will likely result in loss of the cell culture and a free replacement vial will not be provided.
  • Alternate media conditions or sub-culture conditions should not be attempted until a cryopreserved master cell stock (MCS) in the recommended media has been established. Details on how to establish a MCS are provided in the SOPs.
  • PDCs are guaranteed for experimental use for ≥20 passages when maintained in the recommended Complete Media + Y compound following the PDMR SOPs. The PDMR has not taken most cultures beyond this point due to limited incubator space; this does not mean they will not grow for additional passages.
  • CAFs have a finite lifespan in vitro. CAFs are guaranteed for experimental use for up to 3 passages when maintained in the recommended Complete Media + Y compound. Additional population doublings and subcultures are possible, but overall fitness of culture may deteriorate with subsequent passages.
  • PDOrgs are guaranteed for experimental use for ≥10 passages when maintained in the recommended Complete Media + Y compound following the PDMR SOPs. The PDMR has not taken most cultures beyond this point due to limited incubator space; this does not mean they will not grow for additional passages.